Cohance Lifesciences Intrinsic Value
Cohance Lifesciences intrinsic value. Cohance Lifesciences (COHANCE) median intrinsic value is ₹505.26 from 8 valuation models (range ₹138–₹1149), vs current price ₹459.45 — +10.0% upside (Trading Near Calculated Value), margin of safety 9.1%. For current market price and key ratios, visit Cohance Lifesciences share price screener.
COHANCE Valuation Methods Summary — DCF, Graham Number & P/E
Cohance Lifesciences intrinsic value across 8 models vs current price ₹459.45 — upside/downside and value range per method. Analyse Cohance Lifesciences ownership pattern to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹137.83 | ₹110.26 - ₹165.40 | -70.0% | EPS: ₹1.60, Sector P/E: 22x |
| Book Value Method | asset | ₹1148.62 | ₹1033.76 - ₹1263.48 | +150.0% | Book Value/Share: ₹1061.58, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹918.90 | ₹827.01 - ₹1010.79 | +100.0% | Revenue/Share: ₹514.74, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹505.26 | ₹454.73 - ₹555.79 | +10.0% | EBITDA: ₹192.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹823.47 | ₹658.78 - ₹988.16 | +79.2% | CF Growth: 2.8%, Discount: 15% |
| PEG Ratio Method | growth | ₹137.83 | ₹124.05 - ₹151.61 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹137.83 | ₹124.05 - ₹151.61 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹195.49 | ₹175.94 - ₹215.04 | -57.5% | EPS: ₹1.60, BVPS: ₹1061.58 |
COHANCE Intrinsic Value vs Market Price — All Valuation Models
Cohance Lifesciences fair value range ₹138–₹1149 vs current market price ₹459.45 across 8 valuation models. Browse COHANCE cash flow statement for revenue, profit, balance sheet and cash flow data.
COHANCE Intrinsic Value Analysis — Undervalued or Overvalued?
Cohance Lifesciences median intrinsic value ₹505.26, current price ₹459.45 — Trading Near Calculated Value by 10.0%, margin of safety 9.1%.
What is the intrinsic value of COHANCE?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Cohance Lifesciences (COHANCE) is ₹505.26 (median value). With the current market price of ₹459.45, this represents a +10.0% variance from our estimated fair value.
The valuation range spans from ₹137.83 to ₹1148.62, indicating ₹137.83 - ₹1148.62.
Is COHANCE undervalued or overvalued?
Based on our multi-method analysis, Cohance Lifesciences (COHANCE) appears to be trading near calculated value by approximately 10.0%.
COHANCE Financial Health — Key Ratios vs Industry Benchmarks
Cohance Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 0.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.34x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
COHANCE Cash Flow Quality — Operating & Free Cash Flow
Cohance Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹368 Cr | ₹243 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹673 Cr | ₹479 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹359 Cr | ₹178 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹457 Cr | ₹360 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹330 Cr | ₹262 Cr | Positive Free Cash Flow | 8/10 |